id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_sfh5jfwj7bdlbgpfzxyqt223c4	Shadia Jalal	Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group	2009	5	.pdf	application/pdf	3906	441	66	Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group The treatment of patients with metastatic non-small celllung cancer (NSCLC) remains challenging. Therefore, we conducted this trial to evaluate the feasibility of combining higher doses of pemetrexed with cetuximab in cetuximab was determined, patients were subsequently entered onto the phase II portion of the trial and treated at the included acneform rash, alanine aminotransferase elevation, febrile neutropenia, dizziness, and dyspnea. Three patients required dose modifications or delays of either pemetrexed or cetuximab (two of patients with previously treated non-small cell lung cancer. patients with advanced non-small cell lung cancer (NSCLC). of pemetrexed supplemented with folic acid and vitamin b12 in previously treated patients with non-small cell lung cancer. non-small cell lung cancer patients treated with cetuximab and chemotherapy. Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC)	./cache/work_sfh5jfwj7bdlbgpfzxyqt223c4.pdf	./txt/work_sfh5jfwj7bdlbgpfzxyqt223c4.txt